Literature DB >> 862442

The metastatic spread of bronchogenic carcinoma in relation to the interval between resection and death.

W Weiss, J S Gillick.   

Abstract

Information from autopsy was obtained for 125 men who had had lung cancer resected. Metastases were most common among men whose carcinoma was undifferentiated, while the prevalence among those with squamous cell carcinoma and those with adenocarcinoma was about the same. Among men whose cancers were of the latter two types, extrathoracic metastases were more common among men with adenocarcinoma than among those with squamous cell carcinoma. In 44 cases with postoperative death, metastases were found in 36 percent (16 cases). With the passage of time, the incidence of metastases rose rapidly to 85 percent (17/20) 6 to 11 months after resection. These data support the concept that metastatic disease is often present at the time of diagnosis.

Entities:  

Mesh:

Year:  1977        PMID: 862442     DOI: 10.1378/chest.71.6.725

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Jejunal perforation secondary to metastatic bronchogenic carcinoma.

Authors:  A R Quayle; S Holt; R G Clark
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

2.  Small bowel complications of metastatic lung carcinoma.

Authors:  W P Joyce; S P Huddy; C Corbishley; N L Wright
Journal:  Ir J Med Sci       Date:  1990-05       Impact factor: 1.568

Review 3.  Staging non-small cell lung cancer.

Authors:  Leslie Eisenbud Quint
Journal:  Cancer Imaging       Date:  2007-10-22       Impact factor: 3.909

4.  Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer.

Authors:  Dong Soo Lee; Yeon Sil Kim; Chul Seung Kay; Sung Hwan Kim; Chang Dong Yeo; Jin Woo Kim; Seung Joon Kim; Young Kyoon Kim; Yoon Ho Ko; Jin Hyoung Kang; Kyo Young Lee
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.